Next Article in Journal
Metabolic Profiling of Pyrrolizidine Alkaloids in Foliage of Two Echium spp. Invaders in Australia—A Case of Novel Weapons?
Next Article in Special Issue
The Folding of de Novo Designed Protein DS119 via Molecular Dynamics Simulations
Previous Article in Journal
Low T3 State Is Correlated with Cardiac Mitochondrial Impairments after Ischemia Reperfusion Injury: Evidence from a Proteomic Approach
Previous Article in Special Issue
Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors
Review

Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis

1
Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
2
Division of Internal Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3
Department of Molecular Cardiology, Texas Heart Institute, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Salvador Ventura
Int. J. Mol. Sci. 2015, 16(11), 26706-26720; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161125975
Received: 21 September 2015 / Revised: 22 October 2015 / Accepted: 26 October 2015 / Published: 6 November 2015
(This article belongs to the Collection Protein Folding)
The folding of newly synthesized proteins and the maintenance of pre-existing proteins are essential in sustaining a living cell. A network of molecular chaperones tightly guides the folding, intracellular localization, and proteolytic turnover of proteins. Many of the key regulators of cell growth and differentiation have been identified as clients of molecular chaperones, which implies that chaperones are potential mediators of oncogenesis. In this review, we briefly provide an overview of the role of chaperones, including HSP70 and HSP90, in cancer. We further summarize and highlight the emerging the role of chaperonin TRiC (T-complex protein-1 ring complex, also known as CCT) in the development and progression of cancer mediated through its critical interactions with oncogenic clients that modulate growth deregulation, apoptosis, and genome instability in cancer cells. Elucidation of how TRiC modulates the folding and function of oncogenic clients will provide strategies for developing novel cancer therapies. View Full-Text
Keywords: protein-folding; proteostasis; oncogenesis; chaperone; chaperonin; HSP70/90; TRiC/CCT; oncoprotein protein-folding; proteostasis; oncogenesis; chaperone; chaperonin; HSP70/90; TRiC/CCT; oncoprotein
Show Figures

Graphical abstract

MDPI and ACS Style

Roh, S.-H.; Kasembeli, M.; Bakthavatsalam, D.; Chiu, W.; Tweardy, D.J. Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. Int. J. Mol. Sci. 2015, 16, 26706-26720. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161125975

AMA Style

Roh S-H, Kasembeli M, Bakthavatsalam D, Chiu W, Tweardy DJ. Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. International Journal of Molecular Sciences. 2015; 16(11):26706-26720. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161125975

Chicago/Turabian Style

Roh, Soung-Hun, Moses Kasembeli, Deenadayalan Bakthavatsalam, Wah Chiu, and David J. Tweardy 2015. "Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis" International Journal of Molecular Sciences 16, no. 11: 26706-26720. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms161125975

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop